XML 28 R15.htm IDEA: XBRL DOCUMENT
v3.25.2

Note 8 - Financial Instruments With Off-balance-sheet Risk | 6 Months Ended
--- | ---
Jun. 30, 2025
Notes to Financial Statements |
Financial Instruments Disclosure [Text Block] | Note 8. Financial instruments with off-balance-sheet risk In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate. The balance of unfunded commitments to extend credit was $149.0 million and $181.0 million as of June 30, 2025 and December 31, 2024, respectively. Commitments to extend credit consist principally of the unused portions of commitments that obligate the Company to extend credit, often subject to financial or non-financial milestones and other conditions to borrow that must be achieved before the commitment can be drawn. In addition, the commitments generally have fixed expiration dates or other termination clauses. Since commitments may expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements. The following table provides the Company’s unfunded commitments by portfolio company as of June 30, 2025 and December 31, 2024:
|  | June 30, 2025 |  |  | December 31, 2024 |
|  |  |  |  |  | Fair Value of |  |  |  |  |  |  | Fair Value of |
|  |  |  |  |  | Unfunded |  |  |  |  |  |  | Unfunded |
|  | Commitment |  |  | Commitment |  |  | Commitment |  |  | Commitment |
|  | Amount |  |  | Liability |  |  | Amount |  |  | Liability |
|  | (In thousands) |  |  | (In thousands) |
Britecore Holdings, Inc. |  | $ | — |  |  | $ | — |  |  | $ | 2,500 |  |  | $ | 36 |
Candesant Biomedical, Inc. |  |  | — |  |  |  | — |  |  |  | 10,000 |  |  |  | 151 |
Ceribell, Inc. |  |  | 21,000 |  |  |  | 120 |  |  |  | 21,000 |  |  |  | 120 |
Crafty Holdings, Inc. |  |  | 5,000 |  |  |  | 65 |  |  |  | 5,000 |  |  |  | 65 |
Fictiv, Inc. |  |  | — |  |  |  | — |  |  |  | 30,000 |  |  |  | 236 |
GT Medical Technologies, Inc. |  |  | 20,000 |  |  |  | 100 |  |  |  | 20,000 |  |  |  | 100 |
HappyCo. Inc. |  |  | 2,000 |  |  |  | 25 |  |  |  | — |  |  |  | — |
Hometeam Technologies, Inc. |  |  | 10,000 |  |  |  | 100 |  |  |  | 10,000 |  |  |  | 100 |
Long Grove Pharmaceuticals LLC |  |  | 10,000 |  |  |  | 75 |  |  |  | — |  |  |  | — |
MasteryPrep, LLC |  |  | 5,000 |  |  |  | 50 |  |  |  | — |  |  |  | — |
MicroTransponder, Inc. |  |  | 7,500 |  |  |  | — |  |  |  | 15,000 |  |  |  | — |
MML US, Inc. |  |  | 20,000 |  |  |  | 100 |  |  |  | — |  |  |  | — |
OneNetworks, Inc. dba Finexio |  |  | — |  |  |  | — |  |  |  | 5,000 |  |  |  | 26 |
Onkos Surgical, Inc. |  |  | 5,000 |  |  |  | 27 |  |  |  | 5,000 |  |  |  | 27 |
Parse Biosciences, Inc. |  |  | 5,000 |  |  |  | 84 |  |  |  | 15,000 |  |  |  | 252 |
Pivot Bio, Inc. |  |  | 10,000 |  |  |  | 105 |  |  |  | 20,000 |  |  |  | 209 |
SafelyYou, Inc. |  |  | — |  |  |  | — |  |  |  | 5,000 |  |  |  | 73 |
Scientia Vascular, Inc. |  |  | 3,500 |  |  |  | 42 |  |  |  | — |  |  |  | — |
Sparkcharge, Inc. |  |  | 10,000 |  |  |  | 123 |  |  |  | — |  |  |  | — |
Standvast Holdings, LLC |  |  | — |  |  |  | — |  |  |  | 2,500 |  |  |  | 88 |
Supply Network Visibility Holdings, LLC |  |  | 10,000 |  |  |  | 79 |  |  |  | 10,000 |  |  |  | 79 |
Ursa Space Systems Inc. |  |  | 5,000 |  |  |  | 75 |  |  |  | 5,000 |  |  |  | 75 |
Total |  | $ | 149,000 |  |  | $ | 1,170 |  |  | $ | 181,000 |  |  | $ | 1,637 |
The table above also provides the fair value of the Company’s unfunded commitment liability as of June 30, 2025 and December 31, 2024, which totaled $1.2 million and $1.6 million, respectively. The fair value at inception of the delay draw credit agreements is equal to the fees and/or warrants received to enter into these agreements, taking into account the remaining terms of the agreements and the counterparties’ credit profile. The unfunded commitment liability reflects the fair value of these future funding commitments and is included in total investments at fair value on the Company’s consolidated statement of assets and liabilities.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/825/tableOfContent + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration